Advanced Medical Solutions Group plc (AMS) reported unaudited preliminary results for the year ended 31 December 2025, highlighting record full-year sales and adjusted EBITDA with strong organic growth. Key financial and operational highlights include
**Revenue Growth**Total Group revenue increased by 29% to £228.9 million, driven by the full-year impact of the Peters Surgical acquisition and continued growth across key product categories. The Surgical Business Unit saw a 36% increase in revenue to £183.5 million, while the Advanced Woundcare Business Unit grew by 9% to £45.4 million.
**Adjusted EBITDA**Increased by 24% to £49.9 million, reflecting strong profitability and operational performance.
**Net Debt Reduction**Net debt decreased to £50.5 million from £55.8 million in 2024, despite significant investment in transformation projects.
**Dividend Increase**The proposed full-year dividend per share increased by 10% to 2.86p.
**Integration Progress**Successful integration of Peters Surgical and Syntacoll, with commercial synergies already contributing to growth and operational synergies on track.
**Innovation Pipeline**Multiple product approvals expected from 2026 onwards, supporting long-term growth.
**Outlook**AMS expects continued strong growth in Surgical and modest growth in Woundcare, with strong cash generation supporting deleveraging and investment in innovation.
The Board is confident in delivering 2026 revenue and EBITDA in line with market expectations, positioning AMS for sustained growth and long-term value creation.